This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKER Akers Biosciences (AKER) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock About Akers Biosciences Stock (NASDAQ:AKER) 30 days 90 days 365 days Advanced Chart Get Akers Biosciences alerts:Sign Up Key Stats Today's Range$0.11▼$0.1350-Day Range$2.47▼$4.5952-Week Range$1.65▼$6.97Volume5.36 million shsAverage Volume769,876 shsMarket Capitalization$2.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAkers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.Read More… Receive AKER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AKER Stock News HeadlinesClinton native Cam Akers signs with New Orleans SaintsJune 17, 2025 | msn.comFormer Houston Texans RB Cam Akers signs one-year deal with the SaintsJune 14, 2025 | msn.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.June 30 at 2:00 AM | Porter & Company (Ad)New Orleans Saints set to sign RB Cam Akers, but Reddit plots his return to Minnesota VikingsJune 14, 2025 | msn.comSaints sign Cam Akers, adding more competition to their backfieldJune 14, 2025 | msn.comCam Akers Not Worth A Look In Week 10November 10, 2024 | msn.comCam Akers Totals 14 Touches With Aaron Jones Tending To InjuryNovember 10, 2024 | msn.comCam Akers player props odds, tips and betting trends for Week 10 | Vikings vs. JaguarsNovember 10, 2024 | vikingswire.usatoday.comSee More Headlines AKER Stock Analysis - Frequently Asked Questions How were Akers Biosciences' earnings last quarter? Akers Biosciences, Inc. (NASDAQ:AKER) released its earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) EPS for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter. What other stocks do shareholders of Akers Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akers Biosciences investors own include Sorrento Therapeutics (SRNE), Aytu BioPharma (AYTU), ImmunoGen (IMGN), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Vaxart (VXRT) and Neovasc (NVCN). Company Calendar Last Earnings11/15/2018Today6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolNASDAQ:AKER CIK1321834 Webwww.akersbio.com Phone856 848 8698FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.89 million Net MarginsN/A Pretax MarginN/A Return on Equity-87.42% Return on Assets-73.31% Debt Debt-to-Equity RatioN/A Current Ratio9.22 Quick Ratio9.22 Sales & Book Value Annual Sales$1.58 million Price / Sales1.37 Cash FlowN/A Price / Cash FlowN/A Book Value$5.38 per share Price / Book0.02Miscellaneous Outstanding Shares16,653,000Free FloatN/AMarket Cap$2.16 million OptionableNot Optionable Beta0.30 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:AKER) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.